Abstract 4442
Background
Real-world (rw) evidence derived from electronic health records (EHRs) is being explored for use as a comparator to single arm clinical trials in oncology. While RECIST is a standard for assessing tumor response in trials, alternative approaches are needed in rw cohorts. Our objective was to examine whether rwRR derived from abstracted “real-world tumor response” (rwTR) might perform similarly to RECIST-based response rates in a variety of settings to support assessments of drug efficacy.
Methods
We focused on randomized clinical trials supporting FDA approvals in aNSCLC between 2015-2017 (4 trials, 5 arms). We selected rw cohorts of aNSCLC patients from de-identified Flatiron Health EHR-derived database by applying the eligibility criteria of each trial as feasible, following an established internal process; trials were considered infeasible for comparison and not reported when fewer than 30 eligible rw patients were identified at the time of analyses. rwTR was abstracted from unstructured clinical notes and was based on the treating oncologist’s assessment of disease change (e.g., partial response) indicated by imaging at each point of radiographic disease evaluation. We compared the rwRRs observed in rw cohorts to objective response rates (ORRs) from trials.
Results
rw cohorts included 862 patients, and clinical trial cohorts (2 control arms and 3 experimental arms) included 701 patients, see response rates in the table (all except ALEX were confirmed RRs).Table:
1581P
Trial | Trial arm | ORR | rwRR |
---|---|---|---|
CheckMate-017 | E: Nivolumab / 2L+ squamous | 20% (27/135) | 25% (17/68) |
CheckMate-057 | E: Nivolumab / 2L+ nonsquamous | 19% (56/292) | 17% (51/294) |
KEYNOTE-021 | E: Carboplatin, Pembrolizumab, Pemetrexed/ 1L nonsquamous | 55% (33/60) | 42% (37/88) |
KEYNOTE-021 | C: Carboplatin and Pemetrexed/ 1L nonsquamous | 29% (18/63) | 34% (101/294) |
ALEX | C: Crizotinib/ 1L | 75% (114/151) | 68% (80/118) |
Conclusions
Data curated from EHRs of rw patients with aNSCLC can provide estimates of response rates that are comparable to RECIST-based response rates observed in similar patient populations studied in clinical trial settings. These findings demonstrate the potential of leveraging rw cohorts as a comparator to single arm clinical trials in oncology.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Flatiron Health, Inc.
Funding
Flatiron Health Inc., independent subsidiary of the Roche group.
Disclosure
X. Ma: Full / Part-time employment, Flatiron Health, Inc. is an independent subsidiary of the Roche Group.: Flatiron Health, Inc.; Shareholder / Stockholder / Stock options: Roche. N.C. Nussbaum: Shareholder / Stockholder / Stock options, Full / Part-time employment, Flatiron Health, Inc. is an independent subsidiary of the Roche Group.: Flatiron Health, Inc.; Shareholder / Stockholder / Stock options: Roche. K. Magee: Full / Part-time employment, Flatiron Health, Inc. is an independent subsidiary of the Roche Group: Flatiron Health, Inc.; Shareholder / Stockholder / Stock options: Roche. A.B. Bourla: Shareholder / Stockholder / Stock options, Full / Part-time employment, Flatiron Health, Inc. is an independent subsidiary of the Roche Group: Flatiron Health, Inc.; Shareholder / Stockholder / Stock options: Roche. M. Tucker: Shareholder / Stockholder / Stock options, Full / Part-time employment, Flatiron Health, Inc. is an independent subsidiary of the Roche Group.: Flatiron Health, Inc.; Shareholder / Stockholder / Stock options: Roche. L. Bellomo: Shareholder / Stockholder / Stock options, Full / Part-time employment, Flatiron Health, Inc. is an independent subsidiary of the Roche Group: Flatiron Health, Inc.; Shareholder / Stockholder / Stock options: Roche. C. Bennette: Shareholder / Stockholder / Stock options, Full / Part-time employment, Flatiron Health, Inc. is an independent subsidiary of the Roche Group.: Flatiron Health, Inc.; Shareholder / Stockholder / Stock options: Roche.
Resources from the same session
4925 - Prognostic role of CD73 in metastatic Non Small Cell Lung Cancer according to the presence of driver alterations
Presenter: Giulia Galli
Session: Poster Display session 1
Resources:
Abstract
785 - JAK-STAT inhibitor overcomes interferon γ-reduced, NK cell-mediated cytotoxicity in non-small-cell lung cancer cells
Presenter: Riki Okita
Session: Poster Display session 1
Resources:
Abstract
2326 - Low LATS2 expression is associated with poor prognosis in non small cell lung cancer
Presenter: Si-hyong Jang
Session: Poster Display session 1
Resources:
Abstract
5960 - Application of ESCAT and OncoKB scales in Liquid biopsy (LB) in Advanced NSCLC patients (pts): Is it feasible and reliable?
Presenter: Michael McCusker
Session: Poster Display session 1
Resources:
Abstract
4855 - IDH1R132H mutation induces a less aggressive phenotype of glioma cells and affects the radiosensitivity by interacting with Wnt/β-catenin signaling
Presenter: Xuetao Han
Session: Poster Display session 1
Resources:
Abstract
2641 - Impact of Angiopoietin-2 on glioblastoma response to combined chemo-radiotherapy
Presenter: Charly Helaine
Session: Poster Display session 1
Resources:
Abstract
5743 - The Discovery of RNA-aptamers That Selectively Bind and Inhibit Glioblastoma Stem Cells by targeting EphA2
Presenter: Alessandra Affinito
Session: Poster Display session 1
Resources:
Abstract
4160 - Impact of tumor reoxygenation by nanoparticles on Tumor Associated Macrophages (TAMs)
Presenter: Aurélie Ferré
Session: Poster Display session 1
Resources:
Abstract
2474 - Prognostic significance of c-Rel/p50 heterodimer in the tumor microenvironment of uveal melanoma
Presenter: Seema Kashyap
Session: Poster Display session 1
Resources:
Abstract
1769 - Synergistic role of BAP1 and DNA damage response pathway in uveal melanoma and its prognostic significance.
Presenter: JAYANTI JHA
Session: Poster Display session 1
Resources:
Abstract